Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
04:04a PYROGENESIS ANNOUNCES 2016 Q1 RESULTS : Revenues of $1.0MM; Current Backlog $10.6MM
04:03a DELPHI ENERGY : Announces Banking Update
04:03a FEI COMPANY : SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of FEI Company - FEIC
04:02a DELPHI ENERGY : Announces Banking Update
04:01a RIYADH METRO PROJECT : Logistics major challenge
04:01a OMAN AIR : introduces daily flights to Mashhad
04:01a HYUNDAI HCN : Wallan Digital promises new retail experience
04:00a US steel probe 'reflects trade protectionism
03:52a BRIEF : Construction site catches fire near Daytona International Speedway
03:40a BIOGEN : and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA(TM) (daclizumab) for Multiple Sclerosis
Latest news
Advertisement
Hot News 
BOXHILL TECHNOLOGIES : Swings To Profit As Shares Resume Trading (ALLISS)
MAY 31 DEADLINE ALERT : GPM Reminds Investors of the Looming Deadline in the Class Action Lawsuit Against DS Healthcare Group, Inc.
PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticide
DGAP-ADHOC : DO Deutsche Office AG: The Executive Board and the Supervisory Board set
UBISENSE : Notice of AGM
Most Read News
06:20p U S DEPARTMENT OF DEFENSE : Contracts For May 27, 2016
06:10p VERIZON COMMUNICATIONS : unions reach settlement in principle to end strike
09:37p BIOGEN : and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
09:01p WWE® STUDIOS AND SONY PICTURES WORLDWIDE ACQUISITIONS TO PARTNER ON THE MARINE 5 : Battleground
09:40p BIOGEN : and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA(TM) (daclizumab) for Multiple Sclerosis
Most recommended articles
09:14p Next week to provide clues about Fed's, ECB's next steps
08:52p SUMNER REDSTONE : Court sets June 7 hearing on Viacom CEO's removal from Redstone trust
08:16pDJAIRBUS : France Sends Naval Ship to Search for EgyptAir Flight's Black Boxes -- Update
07:15p Gold Prices in Free Fall- Shorts at Risk into NFP
07:15p USD/CAD Risks Further Losses on Upbeat Canada GDP, Slowing U.S. NFP